|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||39.76 - 40.99|
|52 Week Range||34.25 - 44.76|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||43.98|
|Forward Dividend & Yield||0.26 (0.70%)|
|Ex-Dividend Date||Sep 28, 2020|
|1y Target Est||N/A|
As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation (TSE: 4543) has announced that the Terumo Group companies will collectively donate USD 1 million in cash to support the COVID-19 Solidarity Response Fund for the World Health Organization (WHO). Terumo has already donated USD 1 Million in April 2020, and this is the company's second time contributing to the fund.
Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.
Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team as of April 1st, 2021. This reflects Terumo's aspiration to be a Global leader in the field of Interventional Oncology by focusing on improving patient's quality of life and survival.